Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cue Biopharma (CUE) Equity Average (2018 - 2025)

Historic Equity Average for Cue Biopharma (CUE) over the last 8 years, with Q3 2025 value amounting to $15.7 million.

  • Cue Biopharma's Equity Average fell 3316.38% to $15.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.7 million, marking a year-over-year decrease of 3316.38%. This contributed to the annual value of $27.3 million for FY2024, which is 4688.57% down from last year.
  • Cue Biopharma's Equity Average amounted to $15.7 million in Q3 2025, which was down 3316.38% from $12.4 million recorded in Q2 2025.
  • Over the past 5 years, Cue Biopharma's Equity Average peaked at $74.3 million during Q1 2021, and registered a low of $12.0 million during Q1 2025.
  • For the 5-year period, Cue Biopharma's Equity Average averaged around $45.2 million, with its median value being $50.5 million (2023).
  • In the last 5 years, Cue Biopharma's Equity Average skyrocketed by 4884.86% in 2021 and then crashed by 6412.71% in 2025.
  • Over the past 5 years, Cue Biopharma's Equity Average (Quarter) stood at $64.5 million in 2021, then fell by 9.74% to $58.2 million in 2022, then tumbled by 31.51% to $39.9 million in 2023, then plummeted by 46.25% to $21.4 million in 2024, then dropped by 26.74% to $15.7 million in 2025.
  • Its Equity Average was $15.7 million in Q3 2025, compared to $12.4 million in Q2 2025 and $12.0 million in Q1 2025.